Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin...

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Monoclonal antibodies targeting immune checkpoints like PD-L1 and CTLA-4 have advanced cancer therapy.
• However, inconsistent efficacy of solo immunotherapy necessitates novel combination strategies.
• Nanotechnology offers a platform for developing advanced drug delivery systems for combination therapy.

Purpose of the Study:

• To develop and evaluate paclitaxel-loaded, PD-L1-targeted albumin nanoparticles (PD-L1/PTX@HSA) for enhanced cancer treatment.
• To investigate the synergistic effects of combining chemotherapy with immune checkpoint blockade using nanotechnology.
• To assess the in vitro and in vivo efficacy, targeting capabilities, and toxicity of the developed nanomedicine.

Main Methods:

• Human serum albumin (HSA) nanoparticles were loaded with paclitaxel (PTX) using nanoparticle albumin-bound technology.
• Nanoparticles were conjugated with anti-PD-L1 monoclonal antibody via a pH-sensitive linker.
• Characterization included particle size, polydispersity, drug loading, and pH-dependent drug release.
• In vitro and in vivo studies evaluated cellular uptake, tumor accumulation, anti-tumor efficacy, immune cell infiltration, and organ toxicity.

Main Results:

• Successfully prepared PD-L1/PTX@HSA nanoparticles with optimal size (~200 nm) and low polydispersity (~0.12).
• Demonstrated enhanced cancer cell internalization and tumor accumulation in vivo due to PD-L1 modification.
• Exhibited significant in vitro and in vivo tumor inhibition, increased effector T-cell infiltration, and suppressed regulatory T-cells.
• Showcased synergistic anti-tumor effects with CTLA-4 blockade and low organ toxicity.

Conclusions:

• PD-L1/PTX@HSA nanoparticles represent a viable nanotechnology-driven combination therapy for cancer.
• This approach effectively combines chemotherapy with immune checkpoint inhibition for improved anti-tumor immune responses.
• The strategy holds potential for enhancing both quantitative and qualitative clinical efficacy in cancer treatment with reduced toxicity.